Evidence map›Paper›PMID 41838212›Full record

ArticleJournal of neuro-oncology2026

Brain metastases among patients with gynecologic cancers: a single-centre retrospective study of patients treated with brain radiotherapy.

Rania Chehade, Abdullah Al-Humiqani, Lilian Hanna, Arjun Sahgal, Veronika Moravan, Sunit Das, Hany Soliman, Helen Mackay, Katarzyna J Jerzak

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rania ChehadeInstitute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Abdullah Al-HumiqaniAdult Oncology Department, Oncology Cancer of Excellence, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Lilian HannaDepartment of Medical Oncology, London Health Sciences Centre, Western University, London, ON, Canada.
Arjun SahgalDepartment of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
Veronika MoravanVM stats, Toronto, ON, Canada.
Sunit DasInstitute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Hany SolimanDepartment of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
Helen MackayDepartment of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
Katarzyna J JerzakInstitute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, ON, Canada. katarzyna.jerzak@sunnybrook.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveBrain metastases (BrM) among patients with gynecological cancers (GC) have historically been considered rare events, but incidence maybe rising. This study aims to understand treatment patterns and outcomes of patients with GCs and BrM. STUDY

methodsWe conducted a retrospective analysis of patients with GCs and BrM who were treated with radiotherapy at Odette Cancer Centre, Canada, between 2010 and 2022. Descriptive statistics and survival analyses were performed using the R software.

resultsWe identified 94 patients with BrM secondary to GCs. Median age at time of BrM diagnosis was 66 years; median time to BrM development was 30 months, and median follow up time was 7 months. Most patients (63.8%, n = 60) underwent stereotactic radiosurgery (SRS), and 40.4% (n = 38) also had surgery for BrM. Patients with endometrial cancer (EC) accounted for 54.3% (n = 51) of BrM cases followed by ovarian cancer (OC) (25.5%, n = 24) and cervical cancer (CC) (17%, n = 16). Molecular profiling when available revealed 83.3% of EC (n = 10/12) had TP53 overexpression and 33.3% (n = 4/12) had mismatch repair deficiency whereas 20% of OC patients (n = 2/10) had a germline BRCA mutation. Median overall survival (OS) was 10.6 months, longer for OC patients compared to those with EC or CC.

conclusionIn our cohort of patients with GC and BrM treated with radiotherapy, about a third received surgery and two thirds of patients were treated with SRS. Patients with OC and BrM lived longer than those with other primary GCs. Investigation of molecular events that “drive” the development of BrM among patients with GCs is warranted.

Indexed as

Brain NeoplasmsCranial IrradiationGenital Neoplasms, FemaleRadiosurgeryAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansMiddle AgedRetrospective StudiesBrain metastasesGynecological cancerMolecular classificationSurvival

Identifiers

PMID41838212

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.